AXSM vs INTR

For growth investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger pick with 65. 5% revenue growth year-over-year, versus 27. 1% for Inter & Co, Inc. (INTR). Inter & Co, Inc. (INTR) offers the better valuation at 18. 7x trailing P/E (1. 9x forward), making it the more compelling value choice. Analysts rate Axsome Therapeutics, Inc. (AXSM) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Axsome Therapeutics, Inc.

(AXSM) delivered a total return of +295. 0%, compared to +131. 7% for Inter & Co, Inc. (INTR). Over 10 years, the gap is even starker: AXSM returned +1858% versus INTR's +131. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Axsome Therapeutics, Inc.

(AXSM) is the lower-risk stock at 0. 69β versus Inter & Co, Inc. 's 1. 39β — meaning INTR is approximately 102% more volatile than AXSM relative to the S&P 500. On balance sheet safety, Inter & Co, Inc. (INTR) carries a lower debt/equity ratio of 131% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Axsome Therapeutics, Inc.

(AXSM) is pulling ahead at 65. 5% versus 27. 1% for Inter & Co, Inc. (INTR). On earnings-per-share growth, the picture is similar: Inter & Co, Inc. grew EPS 176. 0% year-over-year, compared to 38. 6% for Axsome Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Inter & Co, Inc.

(INTR) is the more profitable company, earning 9. 3% net margin versus -28. 7% for Axsome Therapeutics, Inc. — meaning it keeps 9. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INTR leads at 12. 4% versus -26. 5% for AXSM. At the gross margin level — before operating expenses — AXSM leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for INTR: 53.

1% to $12. 00.

In this comparison, INTR (0.

4% yield) pays a dividend. AXSM does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Axsome Therapeutics, Inc.

(AXSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 69), +1858% 10Y return). Both have compounded well over 10 years (AXSM: +1858%, INTR: +131. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AXSM (Healthcare) and INTR (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.